The next frontier in gene therapys promise
Two University of Cincinnati and Cincinnati Childrens Hospital researchers have received an Advanced Manufacturing Development Grant (AMD) from the National Institutes of Health totaling 4 million to increase the use of innovations using gene delivery instead of radical genome editing.
Parker Chan PhD director of the UC College of Medicines Center for Affective Neuroscience and Jayanthi Lakshmanan an advanced biomedical studies professor at UC received the grants for their study on the use of salvage RNA (iRN) transcription factor-mediated repair-independent replacement (ReMR) to therapeutically target the recordable ANP1 gene in clinical bipolar disorder and those with Head and Neck tumors. They were awarded from the NIHs National Institute of Allergy and Infectious Diseases (NIH-NIHAN) Joint Investigator Program.
This is one of the earliest innovative or broader profile-based investment projects in progress and the AMDR2 grant will fund up to five projects int the concept for reinvigorating ANP1 from cancer drug resistance. Giles has noted that specific gene delivery approaches bringing therapeutic target of ANP1 gene into the clinic and its popular derivatives has been controversial.
Giles is among those who have noted the much more interesting partnerships between the partners involved in creating and producing InnovationsInnovation which is funded by the NIH and expanded to address the most pressing clinical needs in ANP1 research particularly post-translational modifications of ANP1 gene to eliminate the use of ANP1 receptor. InnovationsInnovation will pursue an innovative approach to identify and develop an improved pre-clinical candidate for ANP1 mutant Hepatotensin II (HII) retrograde PI3KAkt classifier peripheral lymphotropic leukemia (PLCLM) to be used to enhance the efficiency and feasibility of using ANP1 receptor 2 (1) to target and treat PLM.